"Just losing the weight and being able to keep it off with the use of these medications is definitely worth the risk of not being regulated by the FDA," Delp said
In March 2025, Roche and Zealand Pharma launched an Up-to-$5.3B obesity collaboration to co-develop and co-commercialize Zealands petrelintide for overweight and obesity indications
Zhong W, Gu B, Gu Y, Groome LJ, Sun J, Wang Y
Primary benefits include: People with chronic eczema, those with symptoms triggered by immune system issues or allergies, and those seeking a complementary approach to traditional treatments may find IV therapy especially beneficial
Here, a simple and efficient assay was established which is based on the quantification of the second reaction product of carnitine monooxygenase (Figures 3A,B)
Haorah et al ., 2008)